Ajanta Pharma Limited (AJANTPHARM) - Total Liabilities
Based on the latest financial reports, Ajanta Pharma Limited (AJANTPHARM) has total liabilities worth Rs13.57 Billion INR (≈ $146.80 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ajanta Pharma Limited - Total Liabilities Trend (2005–2025)
This chart illustrates how Ajanta Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. See Ajanta Pharma Limited current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Ajanta Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Ajanta Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Science Applications International Corporation Common Stock
NYSE:SAIC
|
USA | $3.68 Billion |
|
Lazard Ltd
NYSE:LAZ
|
USA | $3.95 Billion |
|
Universal Display
NASDAQ:OLED
|
USA | $190.74 Million |
|
GF Securities Co. Ltd
F:9GF
|
Germany | €943.99 Billion |
|
GlaxoSmithKline Pharmaceuticals Limited
NSE:GLAXO
|
India | Rs19.57 Billion |
|
MakeMyTrip Limited
F:MY1
|
Germany | €1.87 Billion |
|
MiniMed Group, Inc. Common Stock
NASDAQ:MMED
|
USA | $880.00 Million |
|
Industrias CH S. A. B. de C. V
MX:ICHB
|
Mexico | MX$9.44 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Ajanta Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see AJANTPHARM stock market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.93 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.00 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ajanta Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ajanta Pharma Limited (2005–2025)
The table below shows the annual total liabilities of Ajanta Pharma Limited from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs12.25 Billion ≈ $132.44 Million |
+14.34% |
| 2024-03-31 | Rs10.71 Billion ≈ $115.83 Million |
-17.04% |
| 2023-03-31 | Rs12.91 Billion ≈ $139.62 Million |
+63.17% |
| 2022-03-31 | Rs7.91 Billion ≈ $85.57 Million |
+1.04% |
| 2021-03-31 | Rs7.83 Billion ≈ $84.69 Million |
+8.79% |
| 2020-03-31 | Rs7.20 Billion ≈ $77.85 Million |
+59.62% |
| 2019-03-31 | Rs4.51 Billion ≈ $48.77 Million |
+10.74% |
| 2018-03-31 | Rs4.07 Billion ≈ $44.04 Million |
+59.68% |
| 2017-03-31 | Rs2.55 Billion ≈ $27.58 Million |
-17.57% |
| 2016-03-31 | Rs3.09 Billion ≈ $33.46 Million |
+1.35% |
| 2015-03-31 | Rs3.05 Billion ≈ $33.01 Million |
-14.26% |
| 2014-03-31 | Rs3.56 Billion ≈ $38.50 Million |
+9.51% |
| 2013-03-31 | Rs3.25 Billion ≈ $35.16 Million |
-7.32% |
| 2012-03-31 | Rs3.51 Billion ≈ $37.94 Million |
+19.58% |
| 2011-03-31 | Rs2.93 Billion ≈ $31.72 Million |
-5.43% |
| 2010-03-31 | Rs3.10 Billion ≈ $33.54 Million |
+1.44% |
| 2009-03-31 | Rs3.06 Billion ≈ $33.07 Million |
+36.04% |
| 2008-03-31 | Rs2.25 Billion ≈ $24.31 Million |
+47.15% |
| 2007-03-31 | Rs1.53 Billion ≈ $16.52 Million |
+15.49% |
| 2006-03-31 | Rs1.32 Billion ≈ $14.30 Million |
+11.06% |
| 2005-03-31 | Rs1.19 Billion ≈ $12.88 Million |
-- |
About Ajanta Pharma Limited
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic a… Read more